Should Financial Incentives be Used to Differentially Reward ‘Me-Too’ and Innovative Drugs? Brita Pekarsky Current Opinion 23 September 2012 Pages: 1 - 17
Adverse Drug Interactions Ryan MayhewJune M. McKoyCharles L. Bennett Commentary 23 September 2012 Pages: 19 - 22
The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients Fred J. HellingerWilliam E. Encinosa Original Research Article 23 September 2012 Pages: 23 - 34
Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma Eric DeconinckHouda Miadi-FargierPauline Brice Original Research Article 23 September 2012 Pages: 35 - 46
Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US Virginia M. RosenDouglas C. A. TaylorMilton C. Weinstein Original Research Article 23 September 2012 Pages: 47 - 60
A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing Lisa M. MeckleyJames M. GudgeonDavid L. Veenstra Original Research Article 23 September 2012 Pages: 61 - 74
Erlotinib Katherine A. Lyseng-Williamson Adis Pharmacoeconomic Drug Evaluation 23 September 2012 Pages: 75 - 92